Materias dentro de su búsqueda.
Mostrando 1,241 - 1,260 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.30s Limitar resultados
  1. 1241
    “…Despite specific treatment unfortunately, 20% of primary and 70% of metastatic HER2 tumors develop resistance. HER2 belongs to a gene family, with four members (HER1-4) and these members could be involved in resistance to anti-HER2 therapies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Working together for the family: determination of HER oncogene co-amplifications in breast cancer
  2. 1242
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Alternative splicing of HER2: a novel mediator of EGFR TKI resistance
  3. 1243
    “…As a proof-of-concept compound, AC3573 bound with some specificity to HER3 and abrogated HER2–HER3 complex formation and downstream signalling in cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A small molecule inhibitor of HER3: a proof-of-concept study
  4. 1244
    “…Amplification and overexpression of the human epidermal growth factor receptor-2 (HER-2) gene accelerates cell division and proliferation, and promotes tumor growth and metastasis in various malignant tumors. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Amplification and clinicopathological significance of HER-2 in Kazakh esophageal squamous cell carcinoma
  5. 1245
    “…Based on molecular profiling breast carcinomas are divided into several subtypes depending on the expression of a number of cell surface receptors, e.g., ER, PR, and HER2. The Her2-positive subtype occurs in ~10–15% of all cases of breast cancer, and is characterized by a worse prognosis of patient survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
  6. 1246
    “…HER2 overexpression, which occurs in a fifth of diagnosed breast cancers as well as in other types of solid tumors, has been traditionally linked to greater aggressiveness. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
  7. 1247
    “…In this study, we developed two engineered Human epidermal growth factor receptor 2 (HER2) antigens, K965 and K1117, and compared their immunogenicity to a previously reported truncated HER2 antigen, K684, within a B cell and monocyte-based vaccine (BVAC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
  8. 1248
    por Park, Vivian Y.
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expanding applications of MRI-based radiomics in HER2-positive breast cancer
  9. 1249
    “…BACKGROUND: Guidelines recommend left ventricular ejection fraction (LVEF) assessments every 3 months for cardiotoxicity monitoring during human epidermal growth factor receptor 2 (HER2) targeted therapy. Evidence in support of this practice is lacking. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
  10. 1250
    por Yang, Xue, Wu, Dapeng, Yuan, Shengli
    Publicado 2020
    “…With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
  11. 1251
    “…Pyrotinib is an irreversible dual (EGFR/HER2) tyrosine kinase inhibitor (TKI), newly evaluated for the treatment of HER2-overexpressing cancer types. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
  12. 1252
    “…In 2020 we celebrate the bicentennial of the birth of Florence Nightingale and 110 years from her death (1820–1910). This gives us the opportunity to remember her life and her achievements. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Florence Nightingale bicentennial: 1820–2020. Her contributions to health care improvement
  13. 1253
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Role of birth companion in COVID-19: indispensable for her and an auxiliary hand for us
  14. 1254
    “…Invasive lobular carcinoma with extracellular mucin frequently presents as a palpable mass and may be more likely to be grade 2 to 3 and HER2-positive than classic invasive lobular carcinoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification
  15. 1255
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
  16. 1256
    “…In this study, HER2 RNA aptamers were conjugated to mertansine (DM1) and the anti-cancer effectiveness of the conjugate was evaluated in HER2-overexpressing breast cancer models. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
  17. 1257
    “…This work aims to correlate HER2 and SKP2 protein expression as well as HER2 gene amplification with clinicopathological parameters aiming at identifying potential candidates for targeted therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions
  18. 1258
    “…Despite the development of targeted therapies, tyrosine kinase inhibitors, as well as monoclonal antibodies and their toxin conjugates, all metastatic tumors develop resistance, and nearly one-third of HER2+ breast cancer patients develop resistance to all these therapies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
  19. 1259
    “…BACKGROUND: Although the anti-HER2 antibody trastuzumab augments patient survival in HER2+ breast cancer, a relevant number of patients progress to this treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    MZ1 co-operates with trastuzumab in HER2 positive breast cancer
  20. 1260
    “…HER2 overexpression and dMMR increased with advancing clinical stage. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer
Herramientas de búsqueda: RSS